Sirolimus-induced regression of a large orbital lymphangioma

Orbit. 2019 Feb;38(1):79-80. doi: 10.1080/01676830.2018.1436569. Epub 2018 Feb 6.


Microcystic lymphatic malformations are difficult to treat surgically, especially when located in the orbital apex. Recently, pharmacologic inhibition of the mTOR pathway by sirolimus was reported as a safe and efficacious treatment option for lymphatic malformations (also known as lymphangiomas). We report the case of a young male patient in which a unilateral, retrobulbar lymphatic malformation regressed to a large extent under treatment with 1 mg sirolimus given orally twice a day over a period of six months.

Keywords: Lymphangioma; lymphatic malformation; mTOR; orbit; sirolimus.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / therapeutic use*
  • Humans
  • Lymphangioma / diagnostic imaging
  • Lymphangioma / drug therapy*
  • Magnetic Resonance Imaging
  • Male
  • Orbital Neoplasms / diagnostic imaging
  • Orbital Neoplasms / drug therapy*
  • Sirolimus / administration & dosage
  • Sirolimus / therapeutic use*
  • Treatment Outcome
  • Young Adult


  • Antibiotics, Antineoplastic
  • Sirolimus